甲福明在轻度至中度性结肠炎患者中的辅助作用:一项随机对照研究
Ammena Y Binsaleh1, Sahar M El-Haggar2, Sahar K Hegazy2,3
1Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
Frontiers in pharmacology
|April 7, 2025
概括
甲福明显著降低了性结肠炎 (UC) 患者的疾病活性和炎症标志物. 这项研究表明,甲福明作为一种有益的补充疗法,可以用于管理UC.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 甲福明是一种低血糖药物,具有抗炎和抗氧化特性.
- 这些特性表明慢性炎症性肠道疾病,如性结肠炎 (UC) 的潜在治疗益处.
- 之前的研究在临床前和临床模型中探索了甲福明对UC的保护机制.
研究的目的:
- 评估甲福明作为轻度至中度性结肠炎 (UC) 诊断的患者的辅助疗法的疗效.
主要方法:
- 一项为期6个月的双盲随机对照试验,涉及60名患有轻度至中度UC的患者.
- 参与者被分配到对照组 (美沙胺) 或甲胺组 (甲胺+美沙胺).
- 疾病活动指数 (DAI) 和炎症标志物 (便calprotectin,CRP,IL-10,NO) 在治疗前和后被评估.
主要成果:
- 与仅服用梅沙胺的组相比,甲福林组的DAI,血清CRP,NO和便calprotectin显著降低.
- 在甲胺组观察到IL-10水平的显著增加.
- 在DAI和炎症标志物 (calprotectin,CRP,IL-10) 之间发现了强烈的相关性.
结论:
- 梅特福林显示出作为轻度至中度UC的有效辅助治疗的潜力.
- 它有助于减少疾病活动和关键的炎症标志物,这些标志物与UC病原发生有关.
- 进一步的研究可能会巩固梅特福林在UC管理策略中的作用.
更多相关视频
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
12.0K
05:41Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
2.7K
相关概念视频
01:17Drugs for Treatment of Diarrhea-Predominant IBS
126
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
126
01:21Drugs for Treatment of Constipation-Predominant IBS
117
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
117
01:29Drugs for Treatment of Ulcerative Colitis in IBD
109
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
109
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
108
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
108
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
91
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
91
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
126
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
126